Nafamostat mesylate is a protease inhibitor useful in the treatment of acute pancreatitis. It has anticomplement,
anticoagulant, antikallikrein and other activities, and thus may have additional
utility in the treatment of autoimmune diseases and disseminated intravascular coagulation.
A non-peptide proteaseinhibitor.
Nafamostat is an anticoagulant. Broad spectrum serine protease inhibitor. Reduces eosinophil infiltration, mast cell activation and airway responsiveness in a murine model of asthma
Broad spectrum serine protease inhibitor. Displays selectivity for human tryptase when used at relatively low concentrations. Reduces eosinophil infiltration, mast cell activation and airway responsiveness in a murine model of asthma.
Nafamostat mesylate is a broad spectrum serine protease inhibitor, kallikrein inhibitor, and inhibits blood coagulation. It is also a possible complement inhibitor.
By p-guanidinobenzoic acid hydrochloride, 6-amidino groups-beta naphthal, 4,5-dicyano imidazole, methylene dichloride mix, 0-5 ℃ is stirred 1 hour, then improve temperature to 18-22 ℃, insulation reaction 8-12h, filters washed with dichloromethane, gained solid is 2 with methylsulfonic acid adjust pH, obtains nafamostat mesylate.
Nafamostat Mesylate, also known as FUT-175, is a potent and reversible, broad-spectrum serine protease inhibitor of trypsin, tryptase, and other additional proteases. This small compound has been identified as a key player in the disruption of the inflammatory response via inhibition of the complement system and coagulation cascade. Its wide range of inhibitory activity displays anti-cancer and anti-viral properties and has shown effective inhibition of MERS-CoV by preventing membrane fusion, making it a promising therapeutic candidate against the 2019-nCoV infection.
[1] XINXIN HAN. Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity[J]. Chemico-Biological Interactions, 2019, 297: Pages 80-84. DOI:
10.1016/j.cbi.2018.10.023
